Citation:Pless M, Stupp R, Ris HB, Stahel RA, Weder W, Thierstein S, et al 2015

Citation

Pless M, Stupp R, Ris HB, Stahel RA, Weder W, Thierstein S, et al. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet 2015 Aug 11 Available from: http://www.ncbi.nlm.nih.gov/pubmed/26275735.

Critical appraisals

• Assign a critical appraisal

Critical appraisal link	Clinical question	Assigned to	Status
Pless M, Stupp R, Ris HB, Stahel RA, Weder W, Thierstein S, et al 2015	What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC?	Professor Michael Brown MBBS PhD FRACP FRCPA	completed
Pless M, Stupp R, Ris HB, Stahel RA, Weder W, Thierstein S, et al 2015 1	What is the clinical benefit of the addition of surgery to definitive chemoradiotherapy in stage IIIA (N2) NSCLC? What is the clinical benefit of the addition of neoadjuvant radiotherapy to neoadjuvant chemotherapy in stage IIIA (N2) NSCLC?	Dr Stephen Barnett	completed

Compare quality appraisals for each clinical question

• [[Clinical question:What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC?|]] (compare critical appraisals)
• [[Clinical question:What is the clinical benefit of the addition of surgery to definitive chemoradiotherapy in stage IIIA (N2) NSCLC?, Clinical question:What is the clinical benefit of the addition of neoadjuvant radiotherapy to neoadjuvant chemotherapy in stage IIIA (N2) NSCLC?|]] (compare critical appraisals)

Cited by

1. Emma.dickins/Sandbox
2. What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC?